Clinical Trials Logo

Proton Pump Inhibitor clinical trials

View clinical trials related to Proton Pump Inhibitor.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05647278 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

A RCT of the Efficacy of Tegoprazan 50mg QD in the Treatment of Helicobacter Pylori Infection ( TATH-1 )

TATH-1
Start date: November 1, 2022
Phase: Phase 4
Study type: Interventional

The treatment of helicobacter pylori is very important. The routine treatment is quadruple therapy. In recent years, double therapy has appeared and the curative effect is fair. However, antacid generally uses proton pump inhibitor. The proton pump inhibitor needs double dose to achieve good antacid curative effect. The effect of Tegoprazan used for inhibiting gastric acid is better than proton pump inhibitor. At present, some studies use Tegoprazan instead of common proton pump inhibitor, but almost all use double dose of Tegoprazan. In the previous study, we found that the effect of double dose of proton pump inhibitor can be achieved with 50mg QD of Tegoprazan. Therefore, in this study, 50mg QD of Tegoprazan was used to replace the double dose of proton pump inhibitor to observe the antibacterial effect of Tegoprazan on Helicobacter pylori.